Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Last trade$19.97
Day change+$0.18 (+0.91%)
Day range$19.48 – $20.57
Volume1,163,095
Market cap$1.91B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.91B
Price / earnings
—
Price / book
3.59×
Price / sales
0.72×
EV / sales
1.03×
EV / EBITDA
22.13×
Profitability
Earnings per share
-$0.71
Return on assets
-2.51%
Return on equity
-12.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.98×
Current ratio
0.97×
Quick ratio
0.97×
Cash ratio
0.22×
Cash flow
Price / cash flow
9.46×
Price / free cash flow
11.3×
Free cash flow
$169M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FTRE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$691.5M
$678.2M
$636.5M
$660.5M
$701.3M
$710.3M
$651.3M
$697M
Cost of revenue
$552M
$539M
$512.9M
$529.4M
$578.6M
$576.8M
$534.8M
$556.1M
Gross profit
$139.5M
$139.2M
$123.6M
$131.1M
$122.7M
$133.5M
$116.5M
$140.9M
Selling, general and administrative
$103.8M
$102.1M
$100.5M
$103M
$106.8M
$124.8M
$121.8M
$148.1M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$124.5M
$124.4M
$127M
$144.7M
$131.3M
$463.8M
$636.6M
$196.5M
Operating income
$15M
$14.8M
-$3.4M
-$13.6M
-$8.6M
-$330.3M
-$520.1M
-$55.6M
Interest expense
-$20.2M
-$19.3M
-$19.1M
$0
-$22.6M
-$23.3M
-$22.3M
$0
Income before taxes
-$3.6M
-$1.2M
-$12.3M
-$35.6M
-$28.7M
-$370.7M
-$548M
-$74.9M
Income taxes
-$4.2M
$12M
$11.3M
-$3.1M
-$12.8M
$4.2M
$14.9M
-$1M
Net income
$600K
-$13.2M
-$23.6M
-$32.5M
-$15.9M
-$374.9M
-$562.9M
-$61.2M
Net income attributable to common shareholders
$600K
-$13.2M
-$23.6M
-$32.5M
-$15.9M
-$374.9M
-$562.9M
-$61.2M
EBITDA
$35.7M
$37.1M
$23.1M
$28.1M
$15.9M
$8.7M
-$5.3M
-$7.2M
Basic earnings per share
$0.01
-$0.14
-$0.25
-$0.35
-$0.17
-$4.14
-$6.25
-$0.68
Diluted earnings per share
$0.01
-$0.14
-$0.25
-$0.35
-$0.17
-$4.14
-$6.25
-$0.68
Recent news
Company coverage with links to the original publishers.
Fortrea Holdings Inc. (FTRE) reported Q3 earnings of $0.28 per share, beating consensus estimates of $0.24, and revenues of $691.5 million, exceeding expectations by 3.18%. The company has outperformed the market by 50% year-to-date versus the S&P 500's 13.1% gain. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Fortrea (FTRE), a leading global CRO, announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026, with a fireside chat and 1x1 meetings scheduled.
Vertex Pharmaceuticals is expected to report Q3 2026 earnings of $4.92 per share (up 2.5% YoY) with revenues of $3.4 billion (up 10.6% YoY) on November 2. The company has a positive Earnings ESP of +4.98% combined with a Zacks Rank #3, suggesting a likely earnings beat. However, past performance shows mixed results with only 2 beats in the last 4 quarters.
Fortrea, a leading global contract research organization, has announced a collaboration with Omico, Australia's leading precision oncology screening organization, to accelerate biomarker-driven oncology drug development. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve clinical trial planning, site selection, and patient recruitment for targeted cancer therapies in Australia.
Fortrea, a leading global clinical research organization, has announced a collaboration with Omico, Australia's leading precision oncology platform, to accelerate biomarker-driven oncology research. The partnership combines Fortrea's oncology clinical trial expertise with Omico's PrOSPeCT platform to improve trial design, site selection, and patient recruitment, enabling faster access to relevant clinical trials for cancer patients based on their genomic profiles across Australia.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.